We provide you with 20 years of free, institutional-grade data for MRUS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of MRUS. Explore the full financial landscape of MRUS stock.
| Reported Date | CIK | Ticker | Type |
|---|
Merus N.V(NASDAQ:MRUS) 
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with...
Website: http://www.merus.nl
Founded: 2003
Full Time Employees: 87
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about MRUS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.